Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas, Eisai Tout Pipeline Updates In Face Of Patent Losses: Japanese Earnings Roundup (Part 1 Of 2)

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japanese pharma are responding to patent cliffs much like their Western counterparts, through lifecycle management, cost containment and increased focus on emerging markets. In Part 1 of PharmAsia News' roundup of the Japanese Q1 earnings season, Astellas and Eisai respond to patent loss of blockbuster products by highlighting product development milestones and patent extensions

You may also be interested in...



Eisai's Lorqess Setback Puts Focus Squarely on Eribulin

TOKYO - Eisai's recently acquired weight loss drug Lorqess appears set for failure in the hands of U.S. FDA, and while approval rejection would have a small direct impact on the company, the pending approval of eribulin becomes even more vital to a company trying to offset upcoming years of patent losses

Eisai's Lorqess Setback Puts Focus Squarely on Eribulin

TOKYO - Eisai's recently acquired weight loss drug Lorqess appears set for failure in the hands of U.S. FDA, and while approval rejection would have a small direct impact on the company, the pending approval of eribulin becomes even more vital to a company trying to offset upcoming years of patent losses

Shionogi, Daiichi Sankyo, Mitsubishi Tanabe Await Subsidiary Action For Results: Japanese Earnings Roundup (Part 2 Of 2)

TOKYO - Offering a mixed bag of earnings results, Shionogi, Daiichi Sankyo, and Mitsubishi Tanabe all await action of some sort by subsidiaries to determine their FY2010 outcomes. For Shionogi, that means a need for a U.S. rebound from its Sciele subsdiary, Daiichi Sankyo is holding out for the results of Ranbaxy, and Mitsubishi Tanabe is eyeing the impact of its subsidiary-induced sales suspension. [Editor's note: Part 1 of the Japanese earnings roundup with Astellas and Eisai appeared yesterday (PharmAsia New, Aug. 3, 2010).]

Related Content

UsernamePublicRestriction

Register

SC075774

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel